Carolina Payer-Alarcon

Granada, AN 18014, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Norfloxacin-NSAID Pharmaceutical Salts: Structure-Property Relationships for Enhanced Solubility and Stability.

Norfloxacin-NSAID Pharmaceutical Salts: Structure-Property Relationships for Enhanced Solubility and Stability.

Journal: Crystal growth & design

Published: April 28, 2026

Multicomponent Oxicam-Metformin Salts: Toward a Strategy for Enhancing Solubility and Stability.

Multicomponent Oxicam-Metformin Salts: Toward a Strategy for Enhancing Solubility and Stability.

Journal: Crystal growth & design

Published: November 06, 2025

Enhanced Drug Loading Capacity Using the Dual Metformine-Dexketoprofren Salt on Nanoapatite Materials.

Enhanced Drug Loading Capacity Using the Dual Metformine-Dexketoprofren Salt on Nanoapatite Materials.

Journal: Molecular pharmaceutics

Published: April 25, 2025

Impact of the Coformer Carbon-Chain Length on the Properties of Haloperidol Pharmaceutical Salts.

Impact of the Coformer Carbon-Chain Length on the Properties of Haloperidol Pharmaceutical Salts.

Journal: Crystal growth & design

Published: February 26, 2025

Association between nilotinib-induced hyperbilirubinemia and UGT1A1 polymorphisms in a chronic myeloid leukemia patient.

Association between nilotinib-induced hyperbilirubinemia and UGT1A1 polymorphisms in a chronic myeloid leukemia patient.

Journal: Anti-cancer drugs

Published: February 04, 2025

Sorafenib as maintenance therapy in FLT3+ acute myeloid leukemia post allogeneic transplantation: a case report.

Sorafenib as maintenance therapy in FLT3+ acute myeloid leukemia post allogeneic transplantation: a case report.

Journal: Anti-cancer drugs

Published: November 26, 2024

[Translated article] Impact of pharmaceutical care on adherence to tyrosine kinase inhibitors in chronic myeloid leukaemia.

[Translated article] Impact of pharmaceutical care on adherence to tyrosine kinase inhibitors in chronic myeloid leukaemia.

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Published: September 06, 2024

Dermatological toxicity associated with the use of gilteritinib in relapsed acute myeloid leukemia with FLT3 mutation: a case report.

Dermatological toxicity associated with the use of gilteritinib in relapsed acute myeloid leukemia with FLT3 mutation: a case report.

Journal: Anti-cancer drugs

Published: July 15, 2024

Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era.

Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era.

Journal: Pharmaceutics

Published: October 16, 2023

Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukaemia.

Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukaemia.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: September 25, 2023

Rational Coformer Selection in the Development of 6-Propyl-2-thiouracil Pharmaceutical Cocrystals.

Rational Coformer Selection in the Development of 6-Propyl-2-thiouracil Pharmaceutical Cocrystals.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: February 07, 2023

A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia.

A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia.

Journal: Pharmaceutics

Published: January 14, 2023

Showing 1-12 of 21

Last Updated: 09/26/2026